The review of pre-exposure prophylaxis (PreP) for HIV prevention
DOI:
https://doi.org/10.18041/1794-5232/cultrua.2014v11n1.3808Palavras-chave:
preexposure prophylaxis, tenofovir disoproxil fumarate (TDF), emtricitabine (FTC)Resumo
Human lmmunodeficiency Virus (HlV) epidemic continues to represent a major global health issue. Today, there are several tools available to prevent the spread of HIV infection. However, there are several constraints to the current prevention strategies including low condom use, low acceptance of testing, low awareness of vulnerability and more emphasis on treatment. Prevention strategy is redirected towards reducing acquisition of HIV. Pre-exposure prophylaxis or PrEP is the latest groundbreaking innovation in biomedical research in the prevention of HIV transmission.The purpose of this paper is to review preex ding the current guidelines in the use of PreP.
Downloads
Os dados de download ainda não estão disponíveis.
Referências
1. World Health Organization HIV/AIDS. Fact Sheet No. 360. [Internet] 2013 [Accessioned: May 10, 2014] Retrieved from: http://aids.gov/ hiv-aids-basics/hiv-aids-101/global-statistics/ index.html.
2. Centers for Disease Control and Prevention. HIV in the U.S.: At a glance. [Internet] 2013 [Accessioned: April 15, 2014] Retrieved from: http://www.cdc.gov/hiv/pdf/statistics_basics_ factsheet.pdf.
3. Avert. HIV & AIDS in Latin American. [Internet] 2014 [Accessioned: October 7, 2014] Retrieved from: http://www.avert.org/ hiv-aids-latin-america.htm.
4. Centers for Disease Control and Prevention. About HIV/AIDS. [Internet] 2013[Accessioned: April 15, 2014]Retrieved from: http://www.cdc.gov/hiv/basics/ whatishiv.html#panel0.
5. Naswa S, Marfatia YS. Pre-exposure prophylaxis of HIV. Indian Journal of Sexually Transmitted Disease and AIDS.2011, 32(1);1- 8.
6. Gilead Sciences. Medication guide: Truvada. [Internet] 2013. [Accessioned: April15, 2014] Retrieved from: www.fda/gov/downloads/ drugs/drugsafety/ucm312307.pdf.
7. Peterson L, Taylor D, Roddy R, et al. Tenofovirdisoproxilfumarate for prevention of HIV infection in women: A phase 2, double- blind, randomized, placebo-controlled trial. PLoS Clinical Trials. 2007, 2(5):1-9.
8. Grant RM, Lama J, Anderson PL. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. The New England Journal of Medicine. 2010,363:2587-2599.
9. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. New England Journal of Medicine. 2012,367:399-410.
10. Mutua G, Sanders E, Mugo P, et al. Safety and adherence to intermittent pre-exposure prophylaxis (PreP) for HIV-1 in Africans men who have sex with men and female sex workers. PLoS Clinical Trials. 2012, 7(3);e33103.
11. Thigpen MC, Kebaabetswe PM, Paxton LA, et al.Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. New England Journal of Medicine.2012, 367:43-34.
12. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine. 2012, 367:411-22.
13. Microbicide Trials Network (MTN). MTN statement on decision to discontinue use of oral tenofovir tablets in VOICE, a major HIV prevention study in women. Pittsburgh, PA: Microbicide Trials Network. [Internet] 2013 [Accessioned: February 19, 2014] Retrieved from:http://www.mtnstopshiv.org/node/3619.
14. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection among people who inject drugs in Bangkok, Thailand: arandomized, double-blind, placebo- controlled trial. Lancet.2013,381:2083-2090.
15. Hosek S, Siberry G, Bell M, et al. Project PrePare (ATN 082): Acceptability and feasibility of an HIV pre-exposure prophylaxis (PreP) trial with young men who have sex with men (YMSM). Journal of theAcquired lmmune Deficiency Syndrome.2013,62(4):1-18.
16. US Public Health Services. Preexposure prophylaxis for the prevention of HIV infection in the US – 2014: A clinical practice guidelines. [lnternet] 2014 [Accessioned on eved from: http://www. dc.gov/hiv/pdf/prepguidelines2014.pdf.
2. Centers for Disease Control and Prevention. HIV in the U.S.: At a glance. [Internet] 2013 [Accessioned: April 15, 2014] Retrieved from: http://www.cdc.gov/hiv/pdf/statistics_basics_ factsheet.pdf.
3. Avert. HIV & AIDS in Latin American. [Internet] 2014 [Accessioned: October 7, 2014] Retrieved from: http://www.avert.org/ hiv-aids-latin-america.htm.
4. Centers for Disease Control and Prevention. About HIV/AIDS. [Internet] 2013[Accessioned: April 15, 2014]Retrieved from: http://www.cdc.gov/hiv/basics/ whatishiv.html#panel0.
5. Naswa S, Marfatia YS. Pre-exposure prophylaxis of HIV. Indian Journal of Sexually Transmitted Disease and AIDS.2011, 32(1);1- 8.
6. Gilead Sciences. Medication guide: Truvada. [Internet] 2013. [Accessioned: April15, 2014] Retrieved from: www.fda/gov/downloads/ drugs/drugsafety/ucm312307.pdf.
7. Peterson L, Taylor D, Roddy R, et al. Tenofovirdisoproxilfumarate for prevention of HIV infection in women: A phase 2, double- blind, randomized, placebo-controlled trial. PLoS Clinical Trials. 2007, 2(5):1-9.
8. Grant RM, Lama J, Anderson PL. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. The New England Journal of Medicine. 2010,363:2587-2599.
9. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. New England Journal of Medicine. 2012,367:399-410.
10. Mutua G, Sanders E, Mugo P, et al. Safety and adherence to intermittent pre-exposure prophylaxis (PreP) for HIV-1 in Africans men who have sex with men and female sex workers. PLoS Clinical Trials. 2012, 7(3);e33103.
11. Thigpen MC, Kebaabetswe PM, Paxton LA, et al.Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. New England Journal of Medicine.2012, 367:43-34.
12. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. New England Journal of Medicine. 2012, 367:411-22.
13. Microbicide Trials Network (MTN). MTN statement on decision to discontinue use of oral tenofovir tablets in VOICE, a major HIV prevention study in women. Pittsburgh, PA: Microbicide Trials Network. [Internet] 2013 [Accessioned: February 19, 2014] Retrieved from:http://www.mtnstopshiv.org/node/3619.
14. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection among people who inject drugs in Bangkok, Thailand: arandomized, double-blind, placebo- controlled trial. Lancet.2013,381:2083-2090.
15. Hosek S, Siberry G, Bell M, et al. Project PrePare (ATN 082): Acceptability and feasibility of an HIV pre-exposure prophylaxis (PreP) trial with young men who have sex with men (YMSM). Journal of theAcquired lmmune Deficiency Syndrome.2013,62(4):1-18.
16. US Public Health Services. Preexposure prophylaxis for the prevention of HIV infection in the US – 2014: A clinical practice guidelines. [lnternet] 2014 [Accessioned on eved from: http://www. dc.gov/hiv/pdf/prepguidelines2014.pdf.
Downloads
Publicado
2014-06-01
Edição
Seção
Artículos
Como Citar
The review of pre-exposure prophylaxis (PreP) for HIV prevention. (2014). Cultura Del Cuidado, 11(1), 50-59. https://doi.org/10.18041/1794-5232/cultrua.2014v11n1.3808
